Skip to main content
Clinical Trials/NCT00368641
NCT00368641
Terminated
Phase 2

Treatment-Resistant Heart Failure (HF) and Peritoneal Ultrafiltration (PUF): A Randomized Prospective Trial of Standard Care Versus Standard Care With Peritoneal Ultrafiltration in Patients With Treatment-Resistant Severe Heart Failure

Vantive Health LLC0 sites12 target enrollmentAugust 1, 2006
InterventionsExtraneal

Overview

Phase
Phase 2
Intervention
Extraneal
Conditions
Congestive Heart Failure
Sponsor
Vantive Health LLC
Enrollment
12
Primary Endpoint
All-cause Hospitalization (Unadjusted)
Status
Terminated
Last Updated
9 months ago

Overview

Brief Summary

The objective of the study is to determine if the addition of peritoneal ultrafiltration to standard therapy in treatment-resistant severe heart failure patients will improve fluid balance and functional capacity such that they will spend less time in the hospital and have an improved ambulatory quality of life in comparison to patients who remain on standard therapy alone.

Registry
clinicaltrials.gov
Start Date
August 1, 2006
End Date
April 1, 2008
Last Updated
9 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adults with congestive heart failure (CHF) who remain fluid overloaded despite standard treatment.

Exclusion Criteria

  • Patients who have reversible CHF or have diseases or conditions that would contraindicate the use of peritoneal dialysis.

Arms & Interventions

Intervention

peritoneal dialysis

Intervention: Extraneal

Outcomes

Primary Outcomes

All-cause Hospitalization (Unadjusted)

Time Frame: 6 to 24 months

All-cause hospitalization was defined as (1) hospitalization for any cause of any duration or (2)any ER visit or any clinic visit specifically for congestive heart failure requiring intravenous administration of an inotrope, vasodilator or diuretic.

Similar Trials